In co-culture and in vivo xenograft models, PGM5P4-AS1 suppresses tumor growth and mitigates CD8+ T cell dysfunction, effects that disappear when PTK2 is overexpressed, highlighting PTK2 suppression as essential for the tumor-suppressive action.

PGM5P4-AS1 acts as a negative regulator of PTK2, inhibiting progression of triple-negative breast cancer while alleviating CD8+ T cell dysfunction.

Functional assays show PGM5P4-AS1 inhibits proliferation, colony formation, migration, invasion, and epithelial-mesenchymal transition in TNBC cells, with loss- and gain-of-function studies confirming a PTK2-dependent mechanism.

Source: Niu et al., 2026, Cell Biology and Toxicology; DOI: 10.1007/s10565-026-10285-x.

Upstream silencing of PGM5P4-AS1 in breast cancer occurs via TFAP2A binding to the promoter region and recruitment of HDAC2, reducing H3K27ac and repressing PGM5P4-AS1 transcription.

Mechanistically, PGM5P4-AS1 is mainly cytoplasmic and directly binds RNA helicase UPF1, recruiting UPF1 to PTK2 mRNA and promoting its UPF1-dependent degradation.

Together, the TFAP2A/HDAC2–PGM5P4-AS1–UPF1–PTK2 axis represents a potential therapeutic target to curb breast cancer progression and restore immune function.

Computational analyses of The Cancer Genome Atlas link PGM5P4-AS1 to PTK2 expression and prognosis, with experimental validation showing reduced PGM5P4-AS1 in breast cancer tissues and cell lines.

Clinically, lower PGM5P4-AS1 expression correlates with poorer overall and disease-free survival in breast cancer patients.

The study outlines an epigenetic and post-transcriptional cascade where TFAP2A/HDAC2 suppression of PGM5P4-AS1 prevents PTK2 mRNA decay, thereby promoting tumor progression and CD8+ T cell dysfunction.